Agios Pharmaceuticals (AGIO) Insider Backstrom Buys 14,950 Shares

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

Jay Backstrom picked up 14,950 shares of Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) on June 18, 2026. This purchase formed part of a coordinated wave of insider activity at the biotechnology company on that date. Several other leaders also added shares to their personal holdings, reflecting notable insider interest as the stock navigates the middle portion of its yearly trading range.

Stock Price Position and Range

Shares of Agios Pharmaceuticals recently changed hands at $35.47. That price sits comfortably above the 200-day moving average of $30.75 and just above the 50-day moving average of $34.28. The equity has moved between a 52-week low of $22.24 and a 52-week high of $46.00 over the past year. With a market capitalization of roughly $2.03 billion, the company continues to trade against a backdrop of steady clinical developments in cellular metabolism treatments.

Recent Insider Buys Across Leadership

The June 18, 2026 transactions brought several other prominent names into the buying column alongside Backstrom. Rahul Ballal acquired 14,950 shares on June 18, 2026. David Scadden also picked up 14,950 shares on the same day, and Jacqualyn Fouse added another 14,950 shares. Additional buying came from Cynthia Smith, who purchased 2,816 shares on June 18, 2026, and Sarah Gheuens, the Chief Medical Officer, who bought 3,000 shares on June 18, 2026.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the biotech firm through recent months. On October 7, 2026, Truist Securities maintained a buy rating while adjusting its price target to $37.00. Earlier, B of A Securities maintained a buy rating on September 21, 2026, and moved its target to $50.00. JP Morgan kept a neutral stance with a $34.00 target on August 7, 2026. Citigroup maintained a buy rating with a $52.00 target on July 31, 2026, while Truist Securities issued a $39.00 target on July 31, 2026. HC Wainwright & Co. held a buy rating with a $55.00 target on July 30, 2026, and a $52.00 target on July 21, 2026. RBC Capital maintained a sector perform rating with a $32.00 target on July 7, 2026. Overall, the stock carries a consensus buy recommendation from eight analysts, featuring a mean price target of $46.25.

Biotechnology Focus and Pipeline

Headquartered in Cambridge, Massachusetts, Agios Pharmaceuticals discovers and develops medicines targeting cellular metabolism. Its lead commercial product, PYRUKYND, treats specific types of hemolytic anemias and is evaluated for additional indications like sickle cell disease and thalassemia. The firm employs 539 people and continues to advance various clinical-stage candidates designed for rare genetic and metabolic disorders.

Upcoming Financial Milestones

Investors will look ahead to the company's next earnings report, scheduled for October 29, 2026, for updated financial metrics and pipeline progress. The recent cluster of insider purchases highlights management alignment as the firm moves closer to its late-October updates.